Drug Trial Radar · NCT01176240
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: May 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
225
Actual
Start
Jun 2010
Primary completion
Oct 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- Chelsea TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease. Droxidopa is being studied to determine the effects on blood pressure changes upon standing up (orthostatic challenge). Symptoms and activity measurements, including patient reported falls, will be evaluated to determine the effectiveness of the study drug. Symptoms of NOH may include any of the following: * Dizziness, light-headedness, feeling faint or feeling like you may blackout * Problems with vision (blurring, seeing spots, tunnel vision, etc.) * Weakness * Fatigue * Trouble concentrating * Head \& neck discomfort (the coat hanger syndrome) * Difficulty standing for a short time or a long time * Trouble walking for a short time or a long time The study duration is a maximum of approximately 14 weeks including up to 2 weeks for screening, up to 2 weeks for proper dose finding, followed by an 8 week treatment period and a follow-up visit after 2 weeks. A sufficient number of patients will be screened to allow approximately 211 randomized patients. An extension study is also available to continue treatment if determined appropriate by the study doctor. This Study is NCT01132326 sponsored by Chelsea Therapeutics and is enrolling by invitation only.
Conditions
- Orthostatic Hypotension
- Parkinson's Disease
Interventions
DroxidopaDrug
100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)Time frame: Baseline, Week 8
- 306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1)Time frame: Baseline, Week1
Locations
60 sites in 1 country. Site status is shown where the registry gives one.
Neurology Neurodiagnostic Lab
Alabaster, Alabama
Neurological Physicians of Arizona
Gilbert, Arizona
Xenoscience
Phoenix, Arizona
Barrow Neurology Clinic
Phoenix, Arizona
Banner Health
Sun City, Arizona
Center for Neurosciences
Tucson, Arizona
Northwest Neuro Specialists P.L.L.C.
Tucson, Arizona
Caring Clinical Research Incorporated
Laguna Hills, California
Hoag Memorial Hospital, Presbyterian
Newport Beach, California
Neurosearch - Pasadena
Pasadena, California
Alliance Clinical Research, LLC
Poway, California
Neurosearch, Inc.
Reseda, California
Neurosearch II, Inc.
Ventura, California
Neurology Consultants Medical Group
Whittier, California
Associated Neurologist of Southern Connecticut, PC
Fairfield, Connecticut
Hartford Hospital
Hartford, Connecticut
Eastern Connecticut Neurology Specialists
Manchester, Connecticut
Parkinson's Disease & Movement Disorder Disoder
Boca Raton, Florida
Pharmax Research Clinic, LLC
Miami, Florida
Neurology Associates of Ormond Beach
Ormond Beach, Florida
Neurostudies Inc.
Port Charlotte, Florida
Parkinson's Disease Treatment Center of Southwest Florida
Port Charlotte, Florida
Lovelace Scientific Research
Sarasota, Florida
Tampa General University of South Florida
Tampa, Florida
Vero Neurology
Vero Beach, Florida
Premiere Research Institute
West Palm Beach, Florida
Emory University
Atlanta, Georgia
Neurology Specialists of Decatur Research Center
Decatur, Georgia
Prism Research Group
Rome, Georgia
Alexian Brothers Hospital Network
Elk Grove Village, Illinois
Precise Clinical Research
Topeka, Kansas
North Oaks Health System
Hammond, Louisiana
Harvard Vanguard Medical Associates
Boston, Massachusetts
Detroit Clinical Research Center
Novi, Michigan
Northern Michigan Neurology
Traverse City, Michigan
Gulf Coast Neurology Center, PLLC
Ocean Springs, Mississippi
University of Nevada School of Medicine
Las Vegas, Nevada
Wellness and Research Center
Belvidere, New Jersey
AdvanceMed Research
Lawrenceville, New Jersey
Shore Neurology
Toms River, New Jersey
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.